APO Research
Talk to an analyst

APO RESEARCH · REPORT

RNAi Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global RNAi Therapeutics Market Analysis and Forecast 2026-2032

29 December 2025190 pages

Choose your research edition.

Industry ResearchRNAi Therapeutics Industry Research Report 2026100 pages · $2,950 USDIndustry Growth & TrendsGlobal RNAi Therapeutics Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal RNAi Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNAi Therapeutics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal RNAi Therapeutics Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global RNAi Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for RNAi Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for RNAi Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for RNAi Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for RNAi Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of RNAi Therapeutics include Novartis and Alnylam Pharmaceuticals etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for RNAi Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of RNAi Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for RNAi Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the RNAi Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global RNAi Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for RNAi Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

RNAi Therapeutics Segment by Company

Novartis

Alnylam Pharmaceuticals

RNAi Therapeutics Segment by Type

Subcutaneous Injection

Intravenous Infusion

RNAi Therapeutics Segment by Application

Cancer

Cardiovascular Disease

Genetic Disorder

Other

RNAi Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNAi Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNAi Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNAi Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of RNAi Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of RNAi Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, RNAi Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global RNAi Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Subcutaneous Injection Major Player Table 3. Intravenous Infusion Major Player Table 4. Global RNAi Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Cancer Major Player Table 6. Cardiovascular Disease Major Player Table 7. Genetic Disorder Major Player Table 8. Other Major Player Table 9. RNAi Therapeutics Industry Trends Table 10. RNAi Therapeutics Industry Drivers Table 11. RNAi Therapeutics Industry Opportunities and Challenges Table 12. RNAi Therapeutics Industry Restraints Table 13. Global RNAi Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global RNAi Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 15. Global RNAi Therapeutics Market Share by Region (2021-2026) Table 16. Global RNAi Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 17. Global RNAi Therapeutics Market Share by Region (2027-2032) Table 18. Global RNAi Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 19. Global RNAi Therapeutics Revenue Market Share by Players (2021-2026) Table 20. Global RNAi Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global RNAi Therapeutics Key Players Headquarters & Area Served Table 22. Global RNAi Therapeutics Players, Product Type & Application Table 23. Global RNAi Therapeutics Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global RNAi Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global RNAi Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global RNAi Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 28. Global RNAi Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 29. Global RNAi Therapeutics Revenue Market Share by Type (2021-2026) Table 30. Global RNAi Therapeutics Revenue Market Share by Type (2027-2032) Table 31. Global RNAi Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global RNAi Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 33. Global RNAi Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 34. Global RNAi Therapeutics Revenue Market Share by Application (2021-2026) Table 35. Global RNAi Therapeutics Revenue Market Share by Application (2027-2032) Table 36. Novartis Company Information Table 37. Novartis Business Overview Table 38. Novartis RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Novartis RNAi Therapeutics Product Portfolio Table 40. Novartis Recent Development Table 41. Alnylam Pharmaceuticals Company Information Table 42. Alnylam Pharmaceuticals Business Overview Table 43. Alnylam Pharmaceuticals RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Alnylam Pharmaceuticals RNAi Therapeutics Product Portfolio Table 45. Alnylam Pharmaceuticals Recent Development Table 46. North America RNAi Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 47. North America RNAi Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 48. North America RNAi Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 49. North America RNAi Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 50. North America RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 51. North America RNAi Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 52. North America RNAi Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 53. Europe RNAi Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 54. Europe RNAi Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 55. Europe RNAi Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 56. Europe RNAi Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 57. Europe RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 58. Europe RNAi Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 59. Europe RNAi Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 60. China RNAi Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 61. China RNAi Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 62. China RNAi Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 63. China RNAi Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 64. Asia RNAi Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 65. Asia RNAi Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 66. Asia RNAi Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 67. Asia RNAi Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 68. Asia RNAi Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 69. Asia RNAi Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 70. Asia RNAi Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 71. SAMEA RNAi Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 72. SAMEA RNAi Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 73. SAMEA RNAi Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 74. SAMEA RNAi Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 75. SAMEA RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 76. SAMEA RNAi Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 77. SAMEA RNAi Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. RNAi Therapeutics Image Figure 2. Global RNAi Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RNAi Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Subcutaneous Injection Image Figure 5. Intravenous Infusion Image Figure 6. Global RNAi Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global RNAi Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Cancer Image Figure 9. Cardiovascular Disease Image Figure 10. Genetic Disorder Image Figure 11. Other Image Figure 12. Global RNAi Therapeutics Market Size (US$ Million) & (2021-2032) Figure 13. Global RNAi Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global RNAi Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global RNAi Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global RNAi Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global RNAi Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global RNAi Therapeutics Revenue Market Share by Type (2021-2032) Figure 20. Global RNAi Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global RNAi Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global RNAi Therapeutics Revenue Market Share by Application (2021-2032) Figure 23. North America RNAi Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America RNAi Therapeutics Revenue Share by Type (2021-2032) Figure 25. North America RNAi Therapeutics Revenue Share by Application (2021-2032) Figure 26. North America RNAi Therapeutics Revenue Share by Country (2021-2032) Figure 27. United States RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe RNAi Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe RNAi Therapeutics Revenue Share by Type (2021-2032) Figure 32. Europe RNAi Therapeutics Revenue Share by Application (2021-2032) Figure 33. Europe RNAi Therapeutics Revenue Share by Country (2021-2032) Figure 34. Germany RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China RNAi Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China RNAi Therapeutics Revenue Share by Type (2021-2032) Figure 44. China RNAi Therapeutics Revenue Share by Application (2021-2032) Figure 45. Asia RNAi Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia RNAi Therapeutics Revenue Share by Type (2021-2032) Figure 47. Asia RNAi Therapeutics Revenue Share by Application (2021-2032) Figure 48. Asia RNAi Therapeutics Revenue Share by Region (2021-2032) Figure 49. Japan RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA RNAi Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA RNAi Therapeutics Revenue Share by Type (2021-2032) Figure 57. SAMEA RNAi Therapeutics Revenue Share by Application (2021-2032) Figure 58. SAMEA RNAi Therapeutics Revenue Share by Country (2021-2032) Figure 59. Brazil RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt RNAi Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Subcutaneous Injection
  • Intravenous Infusion
Applications
  • Cancer
  • Cardiovascular Disease
  • Genetic Disorder
  • Other
Companies covered
  • Novartis
  • Alnylam Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 RNAi Therapeutics Market by Type
  3. 1.2.1 Global RNAi Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Subcutaneous Injection
  5. 1.2.3 Intravenous Infusion
  6. 1.3 RNAi Therapeutics Market by Application
  7. 1.3.1 Global RNAi Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Cancer
  9. 1.3.3 Cardiovascular Disease
  10. 1.3.4 Genetic Disorder
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 RNAi Therapeutics Market Dynamics
  1. 2.1 RNAi Therapeutics Industry Trends
  2. 2.2 RNAi Therapeutics Industry Drivers
  3. 2.3 RNAi Therapeutics Industry Opportunities and Challenges
  4. 2.4 RNAi Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global RNAi Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global RNAi Therapeutics Growth Trends by Region
  3. 3.2.1 Global RNAi Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global RNAi Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global RNAi Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global RNAi Therapeutics Revenue by Players
  2. 4.1.1 Global RNAi Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global RNAi Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global RNAi Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global RNAi Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global RNAi Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global RNAi Therapeutics Players, Product Type & Application
  8. 4.5 Global RNAi Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global RNAi Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 RNAi Therapeutics Tier 1, Tier 2, and Tier 3
5 RNAi Therapeutics Market Size by Type
  1. 5.1 Global RNAi Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global RNAi Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global RNAi Therapeutics Revenue Market Share by Type (2021-2032)
6 RNAi Therapeutics Market Size by Application
  1. 6.1 Global RNAi Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global RNAi Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global RNAi Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis RNAi Therapeutics Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Alnylam Pharmaceuticals
  8. 7.2.1 Alnylam Pharmaceuticals Company Information
  9. 7.2.2 Alnylam Pharmaceuticals Business Overview
  10. 7.2.3 Alnylam Pharmaceuticals RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Alnylam Pharmaceuticals RNAi Therapeutics Product Portfolio
  12. 7.2.5 Alnylam Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America RNAi Therapeutics Revenue (2021-2032)
  2. 8.2 North America RNAi Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America RNAi Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America RNAi Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America RNAi Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America RNAi Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America RNAi Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America RNAi Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America RNAi Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America RNAi Therapeutics Revenue by Country
  11. 8.6.1 North America RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America RNAi Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America RNAi Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe RNAi Therapeutics Revenue (2021-2032)
  2. 9.2 Europe RNAi Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe RNAi Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe RNAi Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe RNAi Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe RNAi Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe RNAi Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe RNAi Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe RNAi Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe RNAi Therapeutics Revenue by Country
  11. 9.6.1 Europe RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe RNAi Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe RNAi Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China RNAi Therapeutics Revenue (2021-2032)
  2. 10.2 China RNAi Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China RNAi Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China RNAi Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China RNAi Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China RNAi Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China RNAi Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China RNAi Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China RNAi Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia RNAi Therapeutics Revenue (2021-2032)
  2. 11.2 Asia RNAi Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia RNAi Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia RNAi Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia RNAi Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia RNAi Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia RNAi Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia RNAi Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia RNAi Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia RNAi Therapeutics Revenue by Country
  11. 11.6.1 Asia RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia RNAi Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia RNAi Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA RNAi Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA RNAi Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA RNAi Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA RNAi Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA RNAi Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA RNAi Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA RNAi Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA RNAi Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA RNAi Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA RNAi Therapeutics Revenue by Country
  11. 12.6.1 SAMEA RNAi Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA RNAi Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA RNAi Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst